Cargando…
p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
BACKGROUND: Histone acetyltransferase p300 is a crucial transcriptional coactivator and has been implicated as a poor prognostic factor in human cancers. However, little is known about the substantial functions and mechanisms of p300 in NSCLC proliferation and distant metastasis. METHODS: We constru...
Autores principales: | Hou, Xue, Gong, Run, Zhan, Jianhua, Zhou, Ting, Ma, Yuxiang, Zhao, Yuanyuan, Zhang, Yaxiong, Chen, Gang, Zhang, Zhonghan, Ma, Shuxiang, Chen, Xi, Gao, Fangfang, Hong, Shaodong, Luo, Fan, Fang, Wenfeng, Yang, Yunpeng, Huang, Yan, Chen, Likun, Yang, Haoxian, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992873/ https://www.ncbi.nlm.nih.gov/pubmed/29879950 http://dx.doi.org/10.1186/s12885-018-4559-3 |
Ejemplares similares
-
Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2023) -
Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2018) -
The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2017) -
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020) -
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)